UK cost agency recommends new Sanofi MS pill
LONDON Dec 6 (Reuters) - Britain's healthcare cost watchdog NICE has recommended that the state health service use Sanofi's new multiple sclerosis pill Aubagio, which will be supplied at a discount.
The National Institute for Health and Clinical Excellence (NICE) - the body that decides if drugs should be paid for - said on Friday its final draft guidance recommended Aubagio, or teriflunomide, for adults with relapsing-remitting multiple sclerosis.
The drug's list price is 13,529 pounds ($22,100) per patient a year but the size of the discount has not been disclosed.
On Thursday, NICE said it needed more information before deciding if a separate Sanofi drug for the disease - the injectable treatment Lemtrada - was worth using.
- U.S. and Arab allies launch first strikes on fighters in Syria |
- Israel downs Syrian warplane it says violated its Golan airspace
- Argentina's Fernandez to meet billionaire investor Soros in New York
- Qatar adamant it will host 2022 World Cup despite doubts
- U.S. attack on IS targets in Syria "will be answered" - fighter